Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P29597
UPID:
TYK2_HUMAN
Alternative names:
-
Alternative UPACC:
P29597; Q6QB10; Q96CH0
Background:
Non-receptor tyrosine-protein kinase TYK2 plays a pivotal role in the signaling pathways of cytokines and interferons, influencing cell growth, immunity, and development. It acts by associating with cytokine receptor complexes, activating STAT family members, and regulating gene expression in response to external signals.
Therapeutic significance:
TYK2's involvement in Immunodeficiency 35, characterized by recurrent infections and elevated IgE levels, highlights its potential as a target for therapeutic intervention in immune disorders.